May 4, 2023 – The investigational drug donanemab significantly slowed the decline of Alzheimer’s patients’ ability to think clearly and go about daily tasks in a large study of adults with early signs of the disease, according to early results.

Donanemab – which is made by Eli Lily and targets amyloid plaques, a hallmark of Alzheimer’s disease – met the study’s primary and secondary goals involving measures of cognitive and functional decline, showing “significant clinical benefits,” the drugmaker said in a news release. 

Based on the results, Lilly said it plans to ask the FDA for approval of the drug by the…


By prebo

Leave a Reply

Your email address will not be published. Required fields are marked *